MAGEA3 and non-small cell lung carcinoma: Unfortunately, this study has been stopped in 2014 because adjuvant treatment with the MAGE-A3 immunotherapeutic did not increase disease-free survival compared with placebo in patients with MAGE-A3-positive surgically resected NSCLC [60].